Skip to main content
My Experience
Login Required
Program
Full Program
Browse By Date
Friday, April 22, 2022
Saturday, April 23, 2022
Sunday, April 24, 2022
Browse By Title
Browse By Presenter
CME Program
Non-CME Industry Sessions
Abstracts and ePosters
Browse by Track
Browse by Presenter
Sponsors
Login Required
Attendees
Login Required
CME and Evaluation Information
Login Required
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Toggle navigation
Login
Search
Home
My Experience
Login Required
Program
Full Program
Browse By Date
Friday, April 22, 2022
Saturday, April 23, 2022
Sunday, April 24, 2022
Browse By Title
Browse By Presenter
CME Program
Non-CME Industry Sessions
Abstracts and ePosters
Browse by Track
Browse by Presenter
Sponsors
Login Required
Attendees
Login Required
CME and Evaluation Information
Login Required
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Tweets by 2022 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
4 results found
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
M
Malhotra, Jasnoor
City of Hope Comprehensive Cancer Center
10
:
Waning efficacy of COVID-19 vaccination at 6 months in patients with renal cell carcinoma (RCC)
Jasnoor Malhotra
Favorite
Meza Contreras, Luis
City of Hope Comprehensive Cancer Center
25
:
Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Luis Meza Contreras
Favorite
Motzer, Robert
Memorial Sloan Kettering Cancer Center
22
:
Characterization and Management of Adverse Reactions in Patients With Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study)
Robert Motzer
Favorite
29
:
LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
Robert Motzer
Favorite
Back to Top